KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Gains from Investment Securities (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Gains from Investment Securities for 13 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 121.65% year-over-year to -$1.1 million, compared with a TTM value of $404000.0 through Dec 2025, up 910.0%, and an annual FY2025 reading of $404000.0, up 910.0% over the prior year.
  • Gains from Investment Securities was -$1.1 million for Q4 2025 at Travere Therapeutics, down from $807000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.1 million in Q4 2024 and bottomed at -$15.8 million in Q3 2021.
  • Average Gains from Investment Securities over 5 years is -$232750.0, with a median of $585500.0 recorded in 2024.
  • The sharpest move saw Gains from Investment Securities crashed 6508.0% in 2021, then soared 531.04% in 2025.
  • Year by year, Gains from Investment Securities stood at $1.5 million in 2021, then skyrocketed by 176.85% to $4.0 million in 2022, then crashed by 154.3% to -$2.2 million in 2023, then surged by 331.25% to $5.1 million in 2024, then tumbled by 121.65% to -$1.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for TVTX at -$1.1 million in Q4 2025, $807000.0 in Q3 2025, and -$876000.0 in Q2 2025.